{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:13:00Z","timestamp":1785928380933,"version":"3.56.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 cycles. ctDNA and tumor biopsy were analyzed by high-depth, error-corrected sequencing (limit of detection \u223c10\u22123). Associations between MRD, PET response, and progression-free survival (PFS) were evaluated. Among 84 patients, baseline ctDNA was detected in 98%. After 4 cycles of treatment with R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 14 days) or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), 87.7% had undetectable MRD. Persistence of minimal residual disease after 4 cycles of therapy (MRD4) was associated with shorter PFS (hazard ratio [HR], 78.1; 95% confidence interval [CI], 9.5-641.8). The 1-year PFS was 98.4% (95% CI, 95.4%-100%) for patients with undetectable MRD4 vs 33.3% (95% CI, 13.2%-84.0%) for patients with detectable MRD4 (P &amp;lt; 10^-4). MRD4 showed a higher positive predictive value (89% vs 50%) for disease progression than PET4, (PET after 4 cycles of chemotherapy) maintaining a similar negative predictive value (100% vs 93%). In multivariate analysis, only PET4\u2212\/MRD4\u2212 remained associated with PFS (adjusted HR, 0.07; 95% CI, 0.01-0.90). Plasma ctDNA represents a highly abundant source of genetic markers for tumor fingerprinting and disease monitoring. MRD detection after frontline therapy strongly complements PET response criteria in predicting outcome. These findings support the use of ctDNA monitoring as a valuable tool for future risk-adapted strategies in PMBL. This trial was registered at www.clinicaltrials.gov as NCT04980222.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019108","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:02:13Z","timestamp":1776171733000},"page":"4455-4467","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-007X","authenticated-orcid":false,"given":"Vincent","family":"Camus","sequence":"first","affiliation":[{"name":"1Department of Hematology, Centre Henri Becquerel, Rouen, France"},{"name":"2INSERM U1245, University of Rouen, Rouen, France"},{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-5917","authenticated-orcid":false,"given":"Daphn\u00e9","family":"Krzisch","sequence":"additional","affiliation":[{"name":"4Department of Hemato-oncology, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bruscaggin","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"L\u00e9v\u00eaque","sequence":"additional","affiliation":[{"name":"5Clinical Research Unit, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Viennot","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc-Matthieu","family":"Fornecker","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"7Department of Hematology, H\u00f4pital Necker, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bailly","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Claude Huriez Hospital, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"10Department of Hematology, H\u00f4pital de Brabois, Nancy University Hospital, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, and Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Reims University Hospital, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-7914","authenticated-orcid":false,"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"13Molecular Biology and Hematology Departments, University Hospital, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309), Universit\u00e9 Grenoble Alpes, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Delette","sequence":"additional","affiliation":[{"name":"14Department of Clinical Hematology, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi-Laurent","family":"Damaj","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Caen University Hospital, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Waultier-Rascalou","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Nimes University Hospital, Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lebreton","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Centre Henri Becquerel, Rouen, France"},{"name":"17Jacques Monod Hospital, Groupe Hospitalier du Havre, Montivilliers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-2668","authenticated-orcid":false,"given":"Katell","family":"Le Du","sequence":"additional","affiliation":[{"name":"18H\u00f4pital Priv\u00e9 du Confluent, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-227X","authenticated-orcid":false,"given":"Jean","family":"Galtier","sequence":"additional","affiliation":[{"name":"19Hematology and Cellular Therapy Department, University Hospital of Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"20CHU Rennes, Department of Hematology, University of Rennes, INSERM U1236, EFS, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Morineau","sequence":"additional","affiliation":[{"name":"21Centre Hospitalier D\u00e9partemental de Vend\u00e9e, La Roche-sur-Yon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Centre Hospitalier du Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Lebras","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Leon Berard Cancer Center, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-1983","authenticated-orcid":false,"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[{"name":"25Department of Hematology, H\u00f4pital Saint Vincent de Paul, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bocchetta","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Julien","family":"Viailly","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinciane","family":"Rainville","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruminy","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-4665","authenticated-orcid":false,"given":"M\u00e9lody","family":"Caillot","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico","family":"Terzi di Bergamo","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Piffaretti","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Cristina","family":"Pirosa","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Salehi","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Forestieri","sequence":"additional","affiliation":[{"name":"4Department of Hemato-oncology, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Drieux","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"},{"name":"26Department of Pathology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Liana","family":"Veresezan","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"},{"name":"26Department of Pathology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"27Department of Pathology, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-5744","authenticated-orcid":false,"given":"Marie","family":"Donzel","sequence":"additional","affiliation":[{"name":"27Department of Pathology, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Burel","sequence":"additional","affiliation":[{"name":"5Clinical Research Unit, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-576X","authenticated-orcid":false,"given":"Elodie","family":"Bohers","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Delphine","family":"Lanic","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Penther","sequence":"additional","affiliation":[{"name":"2INSERM U1245, University of Rouen, Rouen, France"},{"name":"28Laboratory of Genetic Oncology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Becker","sequence":"additional","affiliation":[{"name":"29Department of Nuclear Medicine and QuantIF-LITIS\/AIMS, University of Rouen, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-9910","authenticated-orcid":false,"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[{"name":"29Department of Nuclear Medicine and QuantIF-LITIS\/AIMS, University of Rouen, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0611","authenticated-orcid":false,"given":"David","family":"Tonnelet","sequence":"additional","affiliation":[{"name":"29Department of Nuclear Medicine and QuantIF-LITIS\/AIMS, University of Rouen, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Draye-Carbonnier","sequence":"additional","affiliation":[{"name":"29Department of Nuclear Medicine and QuantIF-LITIS\/AIMS, University of Rouen, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Centre Henri Becquerel, Rouen, France"},{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Centre Henri Becquerel, Rouen, France"},{"name":"2INSERM U1245, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"3Laboratory of Experimental Hematology, Institute of Oncology Research, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"},{"name":"30Clinic of Hematology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland"},{"name":"31Division of Hematology, Faculty of Biomedicine, Universit\u00e0 della Svizzera italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-822X","authenticated-orcid":false,"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"6","key":"2026071409580095800_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"19","key":"2026071409580095800_bib2","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2026071409580095800_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409580095800_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3324\/haematol.2023.283446","article-title":"Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients","volume":"109","author":"Cook","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"2026071409580095800_bib5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026071409580095800_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026071409580095800_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-021-00491-7","article-title":"Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study","volume":"11","author":"W\u00e4sterlid","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10343","key":"2026071409580095800_bib8","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"2","key":"2026071409580095800_bib9","doi-asserted-by":"crossref","first-page":"e70091","DOI":"10.1002\/hem3.70091","article-title":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry","volume":"9","author":"Galtier","year":"2025","journal-title":"Hemasphere"},{"issue":"27","key":"2026071409580095800_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"issue":"34","key":"2026071409580095800_bib11","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 Trial results","volume":"42","author":"Martelli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026071409580095800_bib12","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026071409580095800_bib13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"issue":"12","key":"2026071409580095800_bib14","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","article-title":"Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma","volume":"44","author":"Lazarovici","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2026071409580095800_bib15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","article-title":"Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study","volume":"63","author":"Camus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026071409580095800_bib16","doi-asserted-by":"crossref","first-page":"115369","DOI":"10.1016\/j.ejca.2025.115369","article-title":"Primary mediastinal B-cell lymphoma (PMBCL): the LYSA pragmatic guidelines","volume":"220","author":"Renaud","year":"2025","journal-title":"Eur J Cancer"},{"issue":"18","key":"2026071409580095800_bib17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026071409580095800_bib18","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026071409580095800_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","article-title":"Validation of the \u0394SUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical trial","volume":"64","author":"Itti","year":"2023","journal-title":"J Nucl Med"},{"issue":"9","key":"2026071409580095800_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/bloodadvances.2024015577","article-title":"Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma","volume":"9","author":"Camus","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"2026071409580095800_bib21","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"28","key":"2026071409580095800_bib22","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"JCO"},{"issue":"22","key":"2026071409580095800_bib23","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2026071409580095800_bib24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026071409580095800_bib25","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"2026071409580095800_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-8876-1_19","article-title":"Methods for measuring ctDNA in lymphomas","volume":"1881","author":"Rossi","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2026071409580095800_bib27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.23.01053","article-title":"Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes","volume":"42","author":"Noerenberg","year":"2024","journal-title":"JCO"},{"issue":"8","key":"2026071409580095800_bib28","doi-asserted-by":"crossref","first-page":"112930","DOI":"10.1016\/j.celrep.2023.112930","article-title":"Topography of mutational signatures in human cancer","volume":"42","author":"Otlu","year":"2023","journal-title":"Cell Rep"},{"issue":"7920","key":"2026071409580095800_bib29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"issue":"6","key":"2026071409580095800_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s00259-019-04286-8","article-title":"Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume","volume":"46","author":"Ceriani","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2026071409580095800_bib31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026071409580095800_bib32","article-title":"Interim circulating tumor DNA as a prognostic biomarker in the setting of interim PET-based adaptive therapy for DLBCL","volume":"134","author":"Macaulay","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2026071409580095800_bib33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2026071409580095800_bib34","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2026071409580095800_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071409580095800_bib36","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"issue":"33","key":"2026071409580095800_bib37","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"JCO"},{"issue":"8","key":"2026071409580095800_bib38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026071409580095800_bib39","article-title":"Survival patterns of non-randomized patients in the IELSG37 study: Deauville score 4 is not necessarily associated with poor outcome in primary mediastinal lymphoma","volume":"142","author":"Zucca","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026071409580095800_bib40","doi-asserted-by":"crossref","first-page":"101744","DOI":"10.1016\/j.adro.2025.101744","article-title":"Outcomes of primary mediastinal B-cell lymphoma patients with partial metabolic response: a multicenter retrospective analysis","volume":"10","author":"Wattakiyanon","year":"2025","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2026071409580095800_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2026071409580095800_bib42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/cancers16061090","article-title":"Evaluating outcome prediction via baseline, end-of-treatment, and delta radiomics on PET-CT images of primary mediastinal large B-cell lymphoma","volume":"16","author":"Yousefirizi","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"34","key":"2026071409580095800_bib43","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026071409580095800_bib44","first-page":"1573","article-title":"Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma","volume":"110","author":"Soscia","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"2026071409580095800_bib45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026071409580095800_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.19458","article-title":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","volume":"205","author":"Alcoceba","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4455\/2529766\/blooda_adv-2025-019108-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4455\/2529766\/blooda_adv-2025-019108-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:58:12Z","timestamp":1784037492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4455\/567746\/Interim-assessment-by-circulating-tumor-DNA-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":46,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019108","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,24]]}}}